Viral Vaccines Market Global Forecast to 2030

Meticulous Research Projects Hearing Viral Vaccines Market $47.01 Billion by 2031 pen_spark J

Viral Vaccines Market 2024-2031 Comprehensive Analysis of the Viral Vaccines Market Meticulous Research , a renowned global market research firm, has released an insightful report titled Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized), Type (Live Attenuated, mRNA, Inactivated), Virus (Adenovirus, Retrovirus, Plasmid DNA, AAV), Approach, Indication, Application, Packaging Global Forecast to 2031. Download Sample Report Here @ https://www.meticulousresearch.com/download- sample-report/cp_id=5920 Market Overview The global viral vaccines market is poised for substantial growth, projected to reach $47.01 billion by 2031 with a compound annual growth rate (CAGR) of 1.9% from 2024 to 2031. Several factors are contributing to this upward trend, including: A robust pipeline for new vaccine development. Increased governmental emphasis on immunization initiatives. Technological advancements enhancing vaccine administration. The application of inactivated vaccines in various surgical treatments. The expansion capacity of biopharmaceutical products. In addition, the market is witnessing a growing focus on therapeutic vaccines and the rising use of adjuvants in vaccine formulations. Emerging markets also present new growth opportunities, alongside advancements in ultra-low temperature freezers designed to maintain vaccine stability and energy efficiency. Key Market Players The report profiles key players in the viral vaccines market, including: Pfizer, Inc. (U.S.) AstraZeneca plc (U.K.) GlaxoSmithKline plc (U.K.) Sanofi S.A. (Italy) CSL Ltd. (Australia) Mitsubishi Tanabe Pharma Corporation (Japan) Merck & Co., Inc. (U.S.) Moderna, Inc. (U.S.) Johnson & Johnson Services, Inc. (U.S.) Dynavax Technologies Corporation (U.S.) Serum Institute of India Pvt. Ltd (India) Emergent BioSolutions, Inc. (U.S.) Bharat Biotech International Limited (BBIL) (India) Valneva SE (France) Market Segmentation Page 1 of 4 Meticulous Research| sales@meticulousresearch.com

Viral Vaccines Market 2024-2031 The viral vaccines market is segmented comprehensively to facilitate an in-depth analysis: By Form: Liquid Vaccines, Lyophilized Vaccines By Vaccine Type: Live-attenuated Vaccines, Inactivated Vaccines, mRNA Vaccines, Viral Vector Vaccines, Subunit & Conjugate Vaccines, Toxoid Vaccines, Combination Vaccines By Virus Type: Adenovirus, Retrovirus, Plasmid DNA, Adeno-associated Virus (AAV), Lentivirus, Other Virus Types By Route of Administration: Intramuscular (IM), Subcutaneous (SC), Oral, Other Routes By Approach: Preventive Vaccines, Therapeutic Vaccines By Indication: Infectious Diseases, Cancer, Genetic Disorders, Other Indications By Application: Antisense Therapy, Gene Therapy, Cell Therapy, Vaccinology By Packaging: Vials, Prefilled Syringes By Geography: Regional and country-level analysis Market Dynamics Liquid Vaccines Segment Dominance The liquid vaccines segment is anticipated to capture the largest market share in 2024. This segment benefits from: Ease of administration with liquid formulations. No requirement for reconstitution, minimizing potential errors. Simplified logistics compared to lyophilized counterparts. Reduced contamination risks and decreased wastage of accessories. Subunit & Conjugate Vaccines In 2024, the subunit & conjugate vaccines segment is projected to hold a significant share, attributed to: Absence of live components or microorganisms, enhancing safety. Precise pathogen targeting leading to effective immune responses. Long-term immunity with a low risk of immunogenicity. Adenovirus Segment Growth The adenovirus segment is expected to lead in 2024 due to its: Efficiency in gene delivery. Strong immune response capability. High scalability in vaccine production. Collaboration among institutes and organizations is a notable trend in this sector. For example, a partnership formed in January 2024 between ReiThera Srl (Italy), the Ragon Institute of Mass General, MIT, Harvard (U.S.), and the International AIDS Vaccine Initiative, Page 2 of 4 Meticulous Research| sales@meticulousresearch.com

Viral Vaccines Market 2024-2031 Inc. (IAVI) (U.S.) aims to develop a novel HIV vaccine candidate utilizing ReiThera s GRAd vector. Preventive Vaccines Segment Preventive vaccines are set to dominate in 2024, driven by: Increased chronic and infectious disease prevalence. Rising public awareness regarding immunization. Ongoing immunization programs contributing to herd immunity. Infectious Diseases Segment The infectious diseases indication is expected to hold the largest market share due to: Effective disease prevention reducing morbidity and mortality rates. Enhanced global health security and long-term protection. Increasing awareness of vaccine-preventable diseases, with approximately 1.5 million children under five years succumbing to such illnesses annually, as reported by the World Health Organization (WHO). Antisense Therapy Application Antisense therapy is forecasted to command a significant share in 2024. Key factors influencing this growth include: Rising incidence of infectious diseases. Technological advancements in viral vector usage. Growing healthcare expenditure supporting broader application of antisense vaccines. Regional Analysis North America is expected to account for the largest share of the market in 2024. Key factors contributing to this dominance include: A well-established research infrastructure. The presence of leading pharmaceutical companies. Collaborative efforts between research institutes and pharmaceutical entities. Increased public awareness about vaccination amidst emerging pandemic risks. Read Full Report :- https://www.meticulousresearch.com/product/viral-vaccines- market-5920 Conclusion The global viral vaccines market is set for steady growth, driven by innovation, increased governmental support, and rising awareness of public health. As key players continue to Page 3 of 4 Meticulous Research| sales@meticulousresearch.com

Viral Vaccines Market 2024-2031 invest in research and development, the market is expected to evolve rapidly, paving the way for novel therapies and improved healthcare outcomes. About Meticulous Research Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth. Contact Us: Meticulous Research Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research Page 4 of 4 Meticulous Research| sales@meticulousresearch.com